))
Blood-Stage Protein Identified as Key Target for Antimalarial Drugs
Manage episode 419458934 series 3531530
Content provided by Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
A poorly studied malaria protein could serve as a key drug target to help combat the growing problem of resistance.
Transcript
A poorly studied malaria protein – Plasmodium falciparum histone deacetylase 1 – could serve as a key drug target to help combat the growing problem of resistance. The protein helps regulate the ‘intraerythrocytic’ stage of the parasite: a 48-hour cycle in which the parasite invades, replicates, and bursts free from red blood cells, causing disease symptoms. By making this protein fluorescent, researchers found that it is associated with a range of major biological functions that help the parasite progress through this stage, particularly during the ‘trophozoite’ (or mature) stage. When PfHDAC1 was overexpressed, the number of malaria parasites increased – along with the expression of other genes responsible for parasite development. Dihydroartemisinin—a key antimalarial drug—ordinarily interferes with these biological processes, but overexpression of the protein leads to reduced sensitivity and resistance. This research reveals more about the parasite lifecycle in the human body and suggests a new drug target against it.
Source
About The Podcast
The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
67 episodes
Share
